Evidence map›Paper›PMID 37752217›Full record

ReviewLung2023

Lung Microbiome as a Treatable Trait in Chronic Respiratory Disorders.

Filippo Scialò, Maria Vitale, Vito D'Agnano, Domenica Francesca Mariniello, Fabio Perrotta, Alice Castaldo, Susan F M Campbell, Lucio Pastore, Mario Cazzola, Andrea Bianco

Abstract readReview
PubMed Publisher
In one paragraph

Review in Lung, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Filippo Scialò *Department of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.
Maria Vitale *CEINGE-Biotecnologie Avanzate-Franco Salvatore, Naples, Italy.
Vito D'AgnanoDepartment of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.
Domenica Francesca MarinielloDepartment of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.
Fabio PerrottaDepartment of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.
Alice CastaldoDepartment of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Susan F M CampbellDepartment of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.
Lucio PastoreCEINGE-Biotecnologie Avanzate-Franco Salvatore, Naples, Italy.
Mario CazzolaDipartimento di Medicina Sperimentale, University of Rome "Tor Vergata", Rome, Italy.
Andrea BiancoDepartment of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy. andrea.bianco@unicampania.it.
University of Campania "Luigi Vanvitelli" · ITUniversity of Naples Federico II · ITCeinge Biotecnologie Avanzate (Italy) · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Once thought to be a sterile environment, it is now established that lungs are populated by various microorganisms that participate in maintaining lung function and play an important role in shaping lung immune surveillance. Although our comprehension of the molecular and metabolic interactions between microbes and lung cells is still in its infancy, any event causing a persistent qualitative or quantitative variation in the composition of lung microbiome, termed "dysbiosis", has been virtually associated with many respiratory diseases. A deep understanding of the composition and function of the "healthy" lung microbiota and how dysbiosis can cause or participate in disease progression will be pivotal in finding specific therapies aimed at preventing diseases and restoring lung function. Here, we review lung microbiome dysbiosis in different lung pathologies and the mechanisms by which these bacteria can cause or contribute to the severity of the disease. Furthermore, we describe how different respiratory disorders can be caused by the same pathogen, and that the real pathogenetic mechanism is not only dependent by the presence and amount of the main pathogen but can be shaped by the interaction it can build with other bacteria, fungi, and viruses present in the lung. Understanding the nature of this bacteria crosstalk could further our understanding of each respiratory disease leading to the development of new therapeutic strategies.

Indexed as

DysbiosisMicrobiotaBacteriaDisease ProgressionHumansLungLung microbiomeMicrobiomePathological mechanismsRespiratory disorders

Identifiers

PMID37752217
OpenAlexW4387042445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.